Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von Merck Gesellschaft mbH.
ONTARGET - Ongoing telmisartan alone and in combination with ramipril global endpoint trial und TRANSCEND - Telmisartan randomized assessment study in ACE-I intolerant subjects with cardiovascular disease (30 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 21: ONTARGET - primary end point Abb. 22: ONTARGET - secondary end points Abb. 23: TRANSCEND - Telmisartan Randomized AssessmeNt Study in ACE-I INtolerant Subjects with Cardiovascular Disease Aktuelles Bild - Abb. 24: TRANSCEND - background Abb. 25: TRANSCEND - objectives Abb. 26: TRANSCEND - patient profile Abb. 27: TRANSCEND - study design Zum letzten Bild
Abbildung 24: TRANSCEND - background
The HOPE study has shown that ACE inhibition with ramipril reduces the risk of a cardiovascular event in high-risk patients by 22%. However, a considerable proportion of patients who receive an ACE inhibitor develop intolerable side-effects, such as cough, resulting in discontinuation of therapy. [15] TRANSCEND is the parallel study of ONTARGET that will assess the protective effects of telmisartan in patients who are intolerant to ACE inhibitors. 15. Ravid D, Lishner M, Lang R, Ravid M. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol 1994;34:1116-1120.
 
TRANSCEND - background
Vorheriges Bild Nächstes Bild   


Abbildung 24: TRANSCEND - background
The HOPE study has shown that ACE inhibition with ramipril reduces the risk of a cardiovascular event in high-risk patients by 22%. However, a considerable proportion of patients who receive an ACE inhibitor develop intolerable side-effects, such as cough, resulting in discontinuation of therapy. [15] TRANSCEND is the parallel study of ONTARGET that will assess the protective effects of telmisartan in patients who are intolerant to ACE inhibitors. 15. Ravid D, Lishner M, Lang R, Ravid M. Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol 1994;34:1116-1120.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung